Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
T2-18C3 therapeutic antibody · 1 trial · 1 indication
The safety and tolerability of T2-18C3 will be determined by observing patients for clinical adverse events, changes in vital signs, and changes in laboratory parameters such as hematology and chemistry.
| Arm | Type | Description |
|---|---|---|
| T2-18C3 therapeutic antibody | EXPERIMENTAL | 9 subjects will receive the T2-18C3 therapeutic antibody. |
| Name | Type | Description |
|---|---|---|
| T2-18C3 therapeutic antibody | DRUG | 1.25 mg/kg Intravenous infusion every 2 weeks for a total of 4 doses. |
Inclusion Criteria: * American Diabetes Association (ADA) diagnostic criteria for Type 2 Diabetes (T2D) * HbA1c \>7.0% and ≤ 10% * Current T2D duration \> 3 months at Screening * T2D and other diseases must be stable. Stable disease is defined as disease which did not require a change in medication...
Top 20 of 31 competitors
T2-18C3 therapeutic antibody is an investigational drug being studied for the treatment of Type 2 Diabetes. It is currently in Phase 2 clinical development. The drug is being developed by Johnson & Johnson (ticker: JNJ) for the metabolic therapeutic area.
T2-18C3 therapeutic antibody is being developed by Johnson & Johnson, which trades under the ticker JNJ. The company is conducting clinical research on this investigational antibody for Type 2 Diabetes. The drug is currently in Phase 2 development.
T2-18C3 therapeutic antibody is in Phase 2 clinical development. It is an investigational drug being studied for Type 2 Diabetes. The drug has completed one clinical trial, and it is not yet approved by regulatory authorities.
T2-18C3 therapeutic antibody has one completed clinical trial, identified as NCT01427699. This Phase 2 study was titled 'A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes' and enrolled 7 participants in Switzerland.
Yes, T2-18C3 therapeutic antibody is also known as MABp1. The clinical trial NCT01427699 refers to the drug as MABp1 in its title. This investigational antibody is being developed for Type 2 Diabetes and is currently in Phase 2 development.